Innovate with Confidence Xentria Inc. by Your Side

Get regular updates to your inbox. ... Bionews, Inc. ... This site is strictly a news and information website about the disease. It does not provide ... Xentria will transfer the XTMAB-16 intellectual property to Meitheal's parent company, King Friend Industry, if the royalties pass $600 million. If the FDA approves this application, Xentria will be allowed to begin clinical trials of XTMAB-16. The company expects trials could begin ... Vice President, Clinical Development - Xentria, Inc. · Solutions-focused clinical development professional with a diverse background in patient care, ... Sponsor: Xentria, Inc. Overall Status: Active - Recruiting. Phase. 1/2. Condition. Sarcoidosis. Lung Disease. Treatment. XTMAB-16 or Placebo ... This report includes basic information to help you understand the IP strategy and management of XENTRIA INC, such as changes in the number of patents/patent ... Prior to this appointment, Dr Sacco held Vice President and Head of Clinical Development roles at Xentria, Inc. and AnaptysBio, Inc., overseeing ... Essential stats, news, real-time insights on Xentria, Inc.. Connect with decision makers, founders, investors. Explore valuation, funding rounds, reviews. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Infliximab ... Trademark registration by Xentria, Inc. for the trademark XENTRIA.